Trial Profile
Phase I/II trial of Lenalidomide plus Bortezomib combined with Dexamethasone in patients in 1st relapse or primary refractory after first line therapy for Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Apr 2020
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms HOVON 86 MM
- 27 Apr 2020 Trial design presented in Hemato-Oncologie voor Volwassenen Nederland foundation.
- 27 Apr 2020 Status changed from recruiting to completed, according to a Hemato-Oncologie voor Volwassenen Nederland foundation.
- 21 Feb 2017 This study has been completed in Belgium.